FMP
NLS Pharmaceutics AG
NLSP
NASDAQ
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
0.133 USD
0.0002 (0.151%)
About
ceo
Mr. Alexander Zwyer M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://nlspharma.com
exchange
NASDAQ
Description
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
CIK
0001783036
ISIN
CH0523961370
CUSIP
H57830103
Address
The Circle 6
Phone
41 44 512 21 50
Country
CH
Employee
6
IPO Date
Jan 29, 2021
Key Executives
